Brannan Stephen K. 4

What Happened

• Stephen K. Brannan, a director of Serina Therapeutics (SER), received a derivative award of 15,250 shares (transaction code A) on June 17, 2026. The award is reported at $0.00 per share (total reported value $0) and is a grant of equity-based compensation rather than an open-market purchase.

Key Details

• Transaction date: 2026-06-17
• Grant type: Award/Grant (derivative); 15,250 shares @ $0.00 reported
• Vesting: Will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to continued service (per footnote)
• Shares owned after transaction: Not specified in the provided filing summary
• Filing date: 2026-06-22 — filed five days after the transaction (appears later than the typical two-business-day Form 4 reporting window)

Context

• This was a grant of equity (likely stock options or restricted units) that vests over time, not an exercise or sale. Such awards compensate directors and do not by themselves indicate immediate buying or selling activity; they become economically meaningful only if/when vested and exercised or sold.